NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that the antiviral activity of its lead candidate, NV-387, against RSV/A2 is “strong enough to have resulted in full survival of lethally infected animals.” According to the announcement, the company conducted a study that involved extended dosing of NV-387 given orally; those results were compared with a high oral dose of ribavirin, the current approved treatment for RSV, given for the same period. Following this dosing regimen, the NV-387 resulted in complete survival of the mice beyond the 21-day study period, with no signs of pathology (disease) apparent on the last day of observation. In contrast, ribavirin led to death of all animals by 14 days.
“This is an extremely significant result,” said NanoViricides president and chair Anil R. Diwan, PhD, in the press release. “To date, in our lethal infection animal models, we have not observed uniform survival with any of the treatments, including approved drugs, against viruses that include influenza A, smallpox/mpox and coronaviruses. Our studies are designed to be so lethal that the survival lifetime itself can be used as the ranking parameter to evaluate the effectiveness of a treatment. Complete survival is not expected in such studies, unless the drug is extremely effective.”
To view the full press release, visit https://ibn.fm/b00Rg
About NanoViricides Inc.
NanoViricides is a development-stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Additionally, nanoviricides mimic the host-side features that the viruses continue to require in spite of mutations, and therefore, the viruses would be highly unlikely to escape the nanvoricide drugs. The company’s lead drug candidate is NV-387 (drug product NV-CoV-2) for the treatment of RSV, COVID-19, Long COVID, influenza, Bird Flu H5N1 and other respiratory viral infections. NV-387 has successfully completed a phase 1a/1b human clinical trial in healthy subjects with no reported adverse events, even at the highest and repeated dosages. The company is currently focused on advancing NV-387 into phase 2 human clinical trials for treatment of RSV infection. NanoViricides’ other advanced candidate is NV-HHV-1 for the treatment of shingles rash, HSV-1 “cold sores” and HSV-2 “genital ulcers.” The company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. To learn more about the company, visit www.NanoViricides.com. To learn more about the company, visit www.NanoViricides.com.
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]
InvestorWire is powered by IBN